Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis
Authors
Keywords
AKT, BRAF, Colorectal cancer, EGFR, KRAS, PIK3CA, PTEN
Journal
VIRCHOWS ARCHIV
Volume 463, Issue 4, Pages 509-523
Publisher
Springer Nature
Online
2013-08-09
DOI
10.1007/s00428-013-1450-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HER2 testing in gastric cancer: a practical approach
- (2012) Josef Rüschoff et al. MODERN PATHOLOGY
- Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer Survival
- (2012) Xiaoyun Liao et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer
- (2012) Chen Mao et al. PLoS One
- Molecular Genetics of Colorectal Cancer
- (2011) Eric R. Fearon Annual Review of Pathology-Mechanisms of Disease
- KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
- (2011) N Knijn et al. BRITISH JOURNAL OF CANCER
- Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review
- (2011) J. M. Baas et al. ONCOLOGIST
- KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications
- (2010) Antoine Italiano et al. ANNALS OF SURGICAL ONCOLOGY
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
- (2010) Jolien Tol et al. EUROPEAN JOURNAL OF CANCER
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Concordance ofKRAS/BRAFMutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
- (2010) S. Gattenlöhner et al. Journal of Oncology
- The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
- (2009) K. -L. Garm Spindler et al. ANNALS OF ONCOLOGY
- Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
- (2009) F Molinari et al. BRITISH JOURNAL OF CANCER
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
- (2009) Tetsuya Mitsudomi et al. FEBS Journal
- PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
- (2009) Fotios Loupakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
- (2009) Jens Neumann et al. PATHOLOGY RESEARCH AND PRACTICE
- KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis
- (2009) Paloma Cejas et al. PLoS One
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
- (2008) F. Perrone et al. ANNALS OF ONCOLOGY
- BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?
- (2008) Sérgia Velho et al. BMC CANCER
- Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
- (2008) Volker Heinemann et al. CANCER TREATMENT REVIEWS
- K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy
- (2008) M.-C. Etienne-Grimaldi et al. CLINICAL CANCER RESEARCH
- Mutations ofKRASandBRAFin Primary and Matched Metastatic Sites of Colorectal Cancer
- (2008) Salvatore Artale et al. JOURNAL OF CLINICAL ONCOLOGY
- High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
- (2008) D. Santini et al. ONCOLOGIST
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started